drugset / Trial / NCT01359579

A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function

NCT01359579 ↗

Phase 1 Terminated 28 enrolled Anthera Pharmaceuticals
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to compare and evaluate the pharmacokinetic characteristics and the safety of varespladib methyl in mild or moderate renal impairment patients and healthy volunteers.

Timeline

Start
2011-06
Primary completion
2012-04
Completion
2012-06

Outcome

Outcome not reported

Stopped: “Lack of efficacy”

Drugs

EvaluationDrugModalityDoseRoute
Subject Varespladib Methyl Small molecule 500 mg Oral